Flipper, in all due respect, I didn’t hear what you heard. Can you tell me where in the talk with Dr. Liau you heard the negative stuff you talk about?. I didn’t hear anything I haven’t heard before. She is being very careful about pushing her creation, DCVaxL ....unlike other doctors/scientists. I didn’t hear her say anything about digging for subtypes. However, she did talk at length about how different subtypes react differently to DCVax, all stuff we already know.
I will admit that she does not address the use of DCVaxL beyond in brain tumors. That area is completely left out. And we have to realize that she has no interest in those areas.
I think she went out of her way to address generalities for immunotherapy. For example, there are trials that addressed just certain gene types, which would limit their monetary gain, if they had been approved.
I also didn’t hear her say anything about pushing back the combo trial. Can you tell me where in the talk she says that?
Market Data 
Markets 
AI
